Patient characteristics to determine an appropriate maintenance dose of budesonide/formoterol maintenance and reliever therapy

J. Haughney, M. Aubier, R. Buhl, T. Ekstrom, J. Ostinelli, C. P. van Schayck, O. Selroos (Aberdeen, United Kingdom; Paris, Rueil Malmaison, France; Mainz, Germany; Sodertalje, Angelholm, Sweden; Maastricht, Netherlands)

Source: Annual Congress 2009 - Persistent asthma: still an uncontrolled disease requiring new treatments strategies in 2009
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Haughney, M. Aubier, R. Buhl, T. Ekstrom, J. Ostinelli, C. P. van Schayck, O. Selroos (Aberdeen, United Kingdom; Paris, Rueil Malmaison, France; Mainz, Germany; Sodertalje, Angelholm, Sweden; Maastricht, Netherlands). Patient characteristics to determine an appropriate maintenance dose of budesonide/formoterol maintenance and reliever therapy. Eur Respir J 2009; 34: Suppl. 53, 3051

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Budesonide/formoterol maintenance and reliever therapy at two different maintenance doses
Source: Annual Congress 2009 - New bronchodilators
Year: 2009

Comparison of two twice-daily doses of budesonide/formoterol maintenance and reliever therapy
Source: Eur Respir J 2010; 36: 524-530
Year: 2010



Stability of overall asthma control achieved with budesonide/formoterol maintenance + reliever therapy
Source: Annual Congress 2009 - Aspects of clinical asthma
Year: 2009

Budesonide/formoterol maintenance and reliever therapy – effective treatment at a lower cost
Source: Annual Congress 2008 - Rationale of self-education in asthma therapy
Year: 2008

Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus a higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone
Source: Eur Respir J 2006; 28: Suppl. 50, 205s
Year: 2006

Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008

Budesonide/formoterol maintenance and reliever therapy compared with conventional best standard treatment
Source: Annual Congress 2008 - Diagnosing, monitoring and treating respiratory diseases in primary care
Year: 2008

Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD
Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD
Year: 2020




Switching asthma patients using high-dose inhaled steroids to budesonide/formoterol maintenance and reliever therapy
Source: Annual Congress 2010 - Management of airway disease
Year: 2010

The inhaled corticosteroid/long-acting ß-agonist maintenance and reliever therapy regimen: where to from here?
Source: Eur Respir J, 51 (1) 1702338; 10.1183/13993003.02338-2017
Year: 2018



Budesonide/formoterol maintenance and reliever therapy compared to conventional best practice in the treatment of persistent asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 616s
Year: 2007

Budesonide/formoterol maintenance and reliever therapy use in elderly asthma patients
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010

Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma
Source: Eur Respir J, 51 (1) 1701688; 10.1183/13993003.01688-2017
Year: 2018



Episodic high reliever use with budesonide/formoterol maintenance and reliever therapy confers added protection against asthma exacerbations
Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma
Year: 2007


Variation of regular maintenance therapy with budesonide/formoterol of children with asthma
Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma
Year: 2008


Budesonide/formoterol for maintenance and relief vs. higher dose ICS/LABA therapy: outcomes in patients symptomatic on high-dose inhaled corticosteroids (HDICS)
Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment
Year: 2007


Budesonide/formoterol for maintenance and reliever therapy in real-life in Thailand
Source: Annual Congress 2010 - Treatment options for asthma
Year: 2010


Overall asthma control with budesonide/formoterol maintenance and reliever therapy in patients stratified by GINA treatment step
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010

Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?
Source: Eur Respir J 2005; 26: 819-828
Year: 2005